Healthcare | January 05, 2023
Viatris acquires Oyster Point Pharma and Famy Life Sciences
Acquisitions have the potential to add at least $1 billion in sales by 2028
Acquisitions have the potential to add at least $1 billion in sales by 2028
Honan will lead the company in identifying and executing acquisitions that complement Emmes’ existing strong federal government client base, expand its biopharma portfolio, enhance its technology offerings, and broaden its global reach
The MOU will involve product collaboration from both companies with a goal of propelling PFAS destruction in groundwater globally
35 million mosquito nets supplied to countries in sub-Saharan Africa through partners
More women centric initiatives being the need of the hour for holistic development
Tambe has been with Biocon since 1997 and has held diverse leadership and operational roles.
Soluplus branded excipient play a critical role in enabling the drug development process for poorly soluble active pharmaceutical ingredients
To fund the upfront payment, Biocon Biologics has secured USD 1.2 billion of Sustainability Linked Loan
The company offers a wide portfolio of services including integrated doctor-led prescription e-commerce enablement, digital health record management, and smart clinics.
Program will fight the rising incidence of antimicrobial (drug) resistance and improve patient outcomes
Subscribe To Our Newsletter & Stay Updated
